Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 10/20 | 0.49 |
| ▸ | RET | P07949 | 10/20 | 0.49 |
| ▸ | KIF5B | P33176 | 8/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | STK10 | O94804 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.47 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054610 | 1.00 | ENPP1 (0.63) | ENPP1EGFRKDRRETKIF5B | |
| SCHEMBL666884 | 0.93 | ENPP1 (0.63) | ENPP1EGFRKDRRETKIF5B | |
| SCHEMBL30032092 | 0.93 | ENPP1 (0.63) | ENPP1EGFRKDRRETKIF5B | |
| Hydrochloric Acid SCHEMBL28108173 | 0.92 | ENPP1 (0.61) | ENPP1EGFRKDRRETKIF5B | |
| SCHEMBL4020394 | 0.89 | ENPP1 (0.51) | ENPP1EGFRKDRRETKIF5B | |
| SCHEMBL6160435 | 0.89 | ENPP1 (0.84) | ENPP1EGFRKDRRETKIF5B | |
| Acetic Acid SCHEMBL3170544 | 0.86 | ENPP1 (0.56) | ENPP1EGFRKDRRETKIF5B | |
| SCHEMBL364049 | 0.86 | ENPP1 (0.81) | ENPP1EGFRKDRRETFLT1 | |
| SCHEMBL29359187 | 0.86 | ENPP1 (0.81) | ENPP1EGFRKDRRETFLT1 | |
| Hydrochloric Acid SCHEMBL3526531 | 0.84 | ENPP1 (0.79) | ENPP1EGFRKDRFLT1RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325471-A | EGFR inhibitors | 缆图药品公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| EP-4334305-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023249994-A1 | METHODS AND MATERIALS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230116686-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2023-04-13 | — | — | US | disclosed |
| WO-2022236101-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-111065635-B | Novel pyrimidine derivatives as MTH1 inhibitors | 无锡安万生物科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2004043472-A1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
| US-6716847-B2 | ANTIALLERGENS, ANTIINFLAMMATORY | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| US-20030216417-A1 | Substituted anilino-quinoline compounds and use thereof | ASTRAZENECA AB | 2003-11-20 | — | — | US | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
| US-6593333-B1 | Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1117653-B1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| EP-1117653-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020402-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116686-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | ENPP1 2654/4885EGFR 1282/4885KDR 4398/4885 |
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | ENPP1 2745/4885EGFR 3758/4885KDR 3921/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ENPP1 1726/4885EGFR 1/4885KDR 33/4885 |
| US-20030216417-A1 | Substituted anilino-quinoline compounds and use thereof | IL6, IL6ST, IL1A | ENPP1 3464/4885EGFR 1141/4885KDR 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.